Table 1.
Demographics, baseline characteristics and oncological histories of the cohort
| Characteristic | Value |
|---|---|
| Sex (male/female), n | 68/54 |
| Age (years), median (range) | 62 (25–92) |
| Tumour cell type, n (%) | |
| Hepatocellular carcinoma | 26 (21.3) |
| Cholangiocarcinoma | 18 (14.7) |
| Metastatic neuroendocrine carcinoma | 20 (16.4) |
| Metastatic colorectal carcinoma | 29 (23.8) |
| Othera | 29 (23.8) |
| Previous systemic treatment, n (%) | |
| Cytotoxic chemotherapy | 74 (60.7) |
| Bevacizumab | 36 (29.5) |
| Sorafenib | 12 (9.8) |
| Anti-EGFR agents | 18 (14.8) |
| Previous liver-directed treatment, n (%) | |
| Transarterial (chemo)embolization | 27 (22.1) |
| Partial liver resection | 26 (21.3) |
| Radiofrequency ablation | 18 (14.8) |
| External beam radiation therapyb | 8 (6.6) |
| Hepatic radioembolization | 7 (5.7) |
| ECOG performance status, n (%) | |
| 0 | 54 (44.3) |
| 1 | 58 (47.5) |
| 2 | 10 (8.2) |
| Extrahepatic disease, n (%) | 61 (50) |
| Lung | 37 (30.3) |
| Lymph nodes | 16 (13.1) |
| Bone | 10 (8.2) |
| Estimated liver tumour involvement (%), median (range) | 25 (5–70) |
| Maximum tumour diameter (mm), median (range) | 52 (15–133) |
| Liver cirrhosis, n (%) | 22 (18) |
| Microspheres, n (%) | |
| Resin | 98 (80.3) |
| Glass | 24 (19.7) |
| Treatment, n (%) | |
| Whole liver | 97 (79.5) |
| Lobar | 25 (20.5) |
| Administered activity (GBq), median (range) | 1.73 (0.43–6.21) |
EGFR epidermal growth factor receptor
aIncludes sarcoma (five patients), melanoma (four), renal cell carcinoma (three), pancreatic adenocarcinoma (three), oesophageal carcinoma (three), ovarian carcinoma (one), urothelial carcinoma (one), small-cell lung carcinoma (one), lymphoma (one), cervical carcinoma (one), thymic carcinoma (two), breast carcinoma (two), ampullary carcinoma (one), and gastronintestinal junction carcinoma (one)
bThe mean radiation absorbed dose to the liver was determined by dose–volume histogram analysis. All mean liver doses >1 Gy were included